I'd be really surprised if the arbitration is the linchpin that releases the FDA hold. You left out the most probable reason which is the increase in enrollment numbers and change in overall survival vs SOC.
Another possibility is the approval of Keytruda for head and neck cancer may have prompted the FDA place the hold.